Focused On-demand Library for E3 ubiquitin-protein ligase RNF14

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UBS8

UPID:

RNF14_HUMAN

Alternative names:

Androgen receptor-associated protein 54; HFB30; RING finger protein 14

Alternative UPACC:

Q9UBS8; A0AV26; A6NMR2; A8MTW5; B3KN72; B7ZLV2; D3DQE4; O94793; Q6IBV0

Background:

E3 ubiquitin-protein ligase RNF14, also known as Androgen receptor-associated protein 54, plays a pivotal role in the RNF14-RNF25 translation quality control pathway. This pathway activates when a ribosome stalls during translation, leading to the ubiquitination and degradation of translation factors on stalled ribosomes. RNF14 is recruited to these ribosomes by GCN1 and targets EEF1A1/eEF1A for degradation. Beyond its role in stalled ribosome response, RNF14 regulates transcription in Wnt signaling through interaction with TCF transcription factors.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase RNF14 could open doors to potential therapeutic strategies.